IMPAACT 2020
Primary Protocol Team Members
Summary
IMPAACT 2020 is a Phase II, multi-site, open-label, study to evaluate the safety, tolerability, treatment outcomes, and acceptability of all-oral, six-month regimens to treat tuberculosis. The study will enroll infants, children, and adolescents less than 15 years of age living with or without HIV and with confirmed or probable rifampicin-resistant tuberculosis. Participants will be assigned to one of two TB treatment regimens based on their resistance profile for 24 weeks and will be followed for a total of 48 weeks. Parents and caregivers will also be enrolled in the study to participate, with their child, in a socio-behavioral component to assess acceptability, priorities, and preferences for TB treatment.
IMPAACT 2020 Site Selection Update:
The site selection process for IMPAACT 2020 is ongoing as of July 2024 and is open to all IMPAACT sites. Interested sites should review the solicitation email distributed on 22 July 2024 and complete the online site application (available here: https://fhi360.az1.qualtrics.com/jfe/form/SV_7QiyIFNy8lFoSCG) by 12 August 2024.
Any questions should be sent to the IMPAACT 2020 Clinical Research Managers: Emily Brown, Katie McCarthy, and Iris Mustich (embrown@fhi360.org; kmccarthy@fhi360.org; imustich@fhi360.org).